Table of Content

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. SPINAL CORD STIMULATORS HOLDS THE LARGEST MARKET SHARE IN TERMS OF NEUROSTIMULATION SYSTEM
3.2.2. PAIN MANAGEMENT IS THE MAJORLY USED NEUROSTIMULATION APPLICATION

4. MARKET DYNAMICS
4.1. MARKET SCOPE & DEFINITION
4.2. MARKET DRIVERS
4.2.1. HIGH OCCURRENCE OF NEURO DISEASES
4.2.2. DEVELOPMENTS IN TECHNOLOGY
4.2.3. RISING DEMAND FOR MINIMALLY INVASIVE SURGERIES
4.2.4. HIGH MARKET POTENTIAL FOR SCS DEVICES IN NEUROSTIMULATION
4.2.5. INCREASING GERIATRIC POPULATION
4.2.6. FAVORABLE REIMBURSEMENT AND INSURANCE APPROVAL POLICIES
4.3. MARKET RESTRAINTS
4.3.1. HIGH PRICE OF NEUROMODULATION TREATMENT
4.3.2. SIDE EFFECTS OF ASSOCIATED NEUROSTIMULATION DEVICES
4.3.3. ANONYMOUS APPLIANCE OF SCS THERAPY
4.3.4. STRINGENT REGULATORY APPROVALS
4.4. MARKET OPPORTUNITIES
4.4.1. DEVELOPMENT OF INDICATION FOR SCS
4.4.2. INCREASING THE DEMAND FOR NEUROSTIMULATION DEVICES WITHSTANDING MRI SCANS
4.4.3. GROWING OCCURRENCE OF CHRONIC DISCOMFORT
4.5. MARKET CHALLENGES
4.5.1. OBTAINABILITY OF ALTERNATIVE THERAPY
4.5.2. SAFETY CONCERNS

5. MARKET BY SYSTEM
5.1. SPINAL CORD STIMULATORS (SCS)
5.2. DEEP BRAIN STIMULATORS (DBS)
5.3. SACRAL NERVE STIMULATORS (SNS)
5.4. VAGUS NERVE STIMULATORS (VNS)
5.5. GASTRIC ELECTRIC STIMULATOR
5.6. OTHER SYSTEM

6. MARKET BY APPLICATIONS
6.1. PAIN MANAGEMENT
6.2. EPILEPSY
6.3. ESSENTIAL TREMOR
6.4. URINARY AND FECAL INCONTINENCE
6.5. DEPRESSION
6.6. DYSTONIA
6.7. GASTROPARESIS
6.8. PARKINSON’S DISEASE
6.9. OTHER APPLICATIONS

7. KEY ANALYTICS
7.1. PORTER’S FIVE FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTES
7.1.3. BARGAINING POWER OF SUPPLIERS
7.1.4. BARGAINING POWER OF BUYERS
7.1.5. THREAT OF RIVALRY
7.2. ESTIMATION ANALYSIS
7.2.1. INCREASING PREVALENCE OF MENTAL HEALTH PROBLEMS
7.2.2. RISING HEALTHCARE EXPENDITURE ACROSS THE GLOBE
7.2.3. RISING GERIATRIC POPULATION
7.3. VALUE CHAIN ANALYSIS
7.4. PESTLE ANALYSIS
7.5. OPPORTUNITY MATRIX

8. GEOGRAPHICAL ANALYSIS
8.1. EUROPE
8.1.1. THE UNITED KINGDOM
8.1.2. FRANCE
8.1.3. GERMANY
8.1.4. SPAIN
8.1.5. ITALY
8.1.6. REST OF EUROPE

9. COMPETITIVE LANDSCAPE
9.1. MARKET SHARE ANALYSIS
9.2. COMPANY PROFILES
9.2.1. ALEVA NEUROTHERAPEUTICS SA
9.2.1.1. OVERVIEW
9.2.1.2. PRODUCT PORTFOLIO
9.2.1.3. SCOT ANALYSIS
9.2.1.4. STRATEGIC INITIATIVES
9.2.2. BOSTON SCIENTIFIC CORPORATION
9.2.2.1. OVERVIEW
9.2.2.2. PRODUCT PORTFOLIO
9.2.2.3. SCOT ANALYSIS
9.2.2.4. STRATEGIC INITIATIVES
9.2.3. COGENTIX MEDICAL INC
9.2.3.1. OVERVIEW
9.2.3.2. PRODUCT PORTFOLIO
9.2.3.3. SCOT ANALYSIS
9.2.3.4. STRATEGIC INITIATIVES
9.2.4. CYBERONICS INC.
9.2.4.1. OVERVIEW
9.2.4.2. PRODUCT PORTFOLIO
9.2.4.3. SCOT ANALYSIS
9.2.4.4. STRATEGIC INITIATIVES
9.2.5. DEPUY SYNTHES COMPANIES
9.2.5.1. OVERVIEW
9.2.5.2. PRODUCT PORTFOLIO
9.2.5.3. SCOT ANALYSIS
9.2.5.4. STRATEGIC INITIATIVES
9.2.6. DR. LANGER MEDICAL GMBH
9.2.6.1. OVERVIEW
9.2.6.2. PRODUCT PORTFOLIO
9.2.6.3. SCOT ANALYSIS
9.2.6.4. STRATEGIC INITIATIVES
9.2.7. ECTRON LIMITED
9.2.7.1. OVERVIEW
9.2.7.2. PRODUCT PORTFOLIO
9.2.7.3. SCOT ANALYSIS
9.2.7.4. STRATEGIC INITIATIVE
9.2.8. EKSO BIONICS HOLDING INC.
9.2.8.1. OVERVIEW
9.2.8.2. PRODUCT PORTFOLIO
9.2.8.3. SCOT ANALYSIS
9.2.8.4. STRATEGIC INITIATIVE
9.2.9. HELIUS MEDICAL TECHNOLOGIES
9.2.9.1. OVERVIEW
9.2.9.2. PRODUCT PORTFOLIO
9.2.9.3. SCOT ANALYSIS
9.2.9.4. STRATEGIC INITIATIVE
9.2.10. HOCOMA AG
9.2.10.1. OVERVIEW
9.2.10.2. PRODUCT PORTFOLIO
9.2.10.3. SCOT ANALYSIS
9.2.10.4. STRATEGIC INITIATIVE
9.2.11. MEDTRONIC PLC
9.2.11.1. OVERVIEW
9.2.11.2. PRODUCT PORTFOLIO
9.2.11.3. SCOT ANALYSIS
9.2.11.4. STRATEGIC INITIATIVES
9.2.12. NEURONETICS INC.
9.2.12.1. OVERVIEW
9.2.12.2. PRODUCT PORTFOLIO
9.2.12.3. SCOT ANALYSIS
9.2.12.4. STRATEGIC INITIATIVES
9.2.13. NEVRO CORP
9.2.13.1. OVERVIEW
9.2.13.2. PRODUCT PORTFOLIO
9.2.13.3. SCOT ANALYSIS
9.2.13.4. STRATEGIC INITIATIVES
9.2.14. ST. JUDE MEDICAL INC. (ACQUIRED BY ABBOTT LABORATORIES)
9.2.14.1. OVERVIEW
9.2.14.2. PRODUCT PORTFOLIO
9.2.14.3. SCOT ANALYSIS
9.2.14.4. STRATEGIC INITIATIVE
9.2.15. THE MAGSTIM COMPANY LIMITED
9.2.15.1. COMPANY OVERVIEW
9.2.15.2. PRODUCT PORTFOLIO
9.2.15.3. SCOT ANALYSIS
9.2.15.4. STRATEGIC INITIATIVES


TABLE LIST
TABLE 1 EUROPE NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
TABLE 2 EUROPE NEUROSTIMULATION DEVICE MARKET BY SYSTEM 2019-2027 ($ MILLION)
TABLE 3 EUROPE SPINAL CORD STIMULATORS MARKET 2019-2027 ($ MILLION)
TABLE 4 EUROPE DEEP BRAIN STIMULATORS MARKET 2019-2027 ($ MILLION)
TABLE 5 EUROPE SACRAL NERVE STIMULATORS MARKET 2019-2027 ($ MILLION)
TABLE 6 EUROPE VAGUS NERVE STIMULATORS MARKET 2019-2027 ($ MILLION)
TABLE 7 EUROPE GASTRIC ELECTRIC STIMULATOR MARKET 2019-2027 ($ MILLION)
TABLE 8 EUROPE OTHER SYSTEM MARKET 2019-2027 ($ MILLION)
TABLE 9 EUROPE NEUROSTIMULATION DEVICE MARKET BY APPLICATIONS 2019-2027 ($ MILLION)
TABLE 10 EUROPE PAIN MANAGEMENT MARKET 2019-2027 ($ MILLION)
TABLE 11 EUROPE EPILEPSY MARKET 2019-2027 ($ MILLION)
TABLE 12 EUROPE ESSENTIAL TREMOR MARKET 2019-2027 ($ MILLION)
TABLE 13 EUROPE URINARY AND FECAL INCONTINENCE MARKET 2019-2027 ($ MILLION)
TABLE 14 EUROPE DEPRESSION MARKET 2019-2027 ($ MILLION)
TABLE 15 EUROPE DYSTONIA MARKET 2019-2027 ($ MILLION)
TABLE 16 EUROPE GASTROPARESIS MARKET 2019-2027 ($ MILLION)
TABLE 17 EUROPE PARKINSON’S DISEASE MARKET 2019-2027 ($ MILLION)
TABLE 18 EUROPE OTHER APPLICATIONS MARKET 2019-2027 ($ MILLION)
TABLE 19 EUROPE NEUROSTIMULATION DEVICE MARKET BY GEOGRAPHY 2019-2027, (IN $ BILLION)
TABLE 20 EUROPE NEUROSTIMULATION DEVICE MARKET BY COUNTRY 2019-2027 ($ MILLION)


FIGURES LIST
FIGURE 1 EUROPE NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 2 EUROPE NEUROSTIMULATION DEVICE MARKET SHARE BY SYSTEM 2018 & 2027 (%)
FIGURE 3 EUROPE NEUROSTIMULATION DEVICE MARKET BY SPINAL CORD STIMULATORS 2019-2027 ($ MILLION)
FIGURE 4 EUROPE NEUROSTIMULATION DEVICE MARKET BY DEEP BRAIN STIMULATORS 2019-2027 ($ MILLION)
FIGURE 5 EUROPE NEUROSTIMULATION DEVICE MARKET BY SACRAL NERVE STIMULATORS 2019-2027 ($ MILLION)
FIGURE 6 EUROPE NEUROSTIMULATION DEVICE MARKET BY VAGUS NERVE STIMULATORS 2019-2027 ($ MILLION)
FIGURE 7 EUROPE NEUROSTIMULATION DEVICE MARKET BY GASTRIC ELECTRIC STIMULATOR 2019-2027 ($ MILLION)
FIGURE 8 EUROPE NEUROSTIMULATION DEVICE MARKET BY OTHER SYSTEM 2019-2027 ($ MILLION)
FIGURE 9 EUROPE NEUROSTIMULATION DEVICE MARKET SHARE BY APPLICATIONS 2018 & 2027 (%)
FIGURE 10 EUROPE NEUROSTIMULATION DEVICE MARKET BY PAIN MANAGEMENT 2019-2027 ($ MILLION)
FIGURE 11 EUROPE NEUROSTIMULATION DEVICE MARKET BY EPILEPSY 2019-2027 ($ MILLION)
FIGURE 12 EUROPE NEUROSTIMULATION DEVICE MARKET BY ESSENTIAL TREMOR 2019-2027 ($ MILLION)
FIGURE 13 EUROPE NEUROSTIMULATION DEVICE MARKET BY URINARY AND FECAL INCONTINENCE 2019-2027 ($ MILLION)
FIGURE 14 EUROPE NEUROSTIMULATION DEVICE MARKET BY DEPRESSION 2019-2027 ($ MILLION)
FIGURE 15 EUROPE NEUROSTIMULATION DEVICE MARKET BY DYSTONIA 2019-2027 ($ MILLION)
FIGURE 16 EUROPE NEUROSTIMULATION DEVICE MARKET BY GASTROPARESIS 2019-2027 ($ MILLION)
FIGURE 17 EUROPE NEUROSTIMULATION DEVICE MARKET BY PARKINSON’S DISEASE 2019-2027 ($ MILLION)
FIGURE 18 EUROPE NEUROSTIMULATION DEVICE MARKET BY OTHER APPLICATIONS 2019-2027 ($ MILLION)
FIGURE 19 PORTER’S FIVE FORCE MODEL
FIGURE 20 PREVALENCE OF MENTAL HEALTH DISORDERS ACROSS THE GLOBE BETWEEN PERIOD 2012 AND 2020 (MILLION)
FIGURE 21 RISING GERIATRIC POPULATION ACROSS THE GLOBE FOR PERIOD 2014-2020 (MILLION)
FIGURE 22 VALUE CHAIN OF NEUROSTIMULATION DRUGS
FIGURE 23 THE UNITED KINGDOM NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 24 FRANCE NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 25 GERMANY NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 26 SPAIN NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 27 ITALY NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 28 REST OF EUROPE NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 29 NEUROSTIMULATION DEVICE COMPANY MARKET SHARE 2018 (%)



List of Figures


FIGURES LIST
FIGURE 1 EUROPE NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 2 EUROPE NEUROSTIMULATION DEVICE MARKET SHARE BY SYSTEM 2018 & 2027 (%)
FIGURE 3 EUROPE NEUROSTIMULATION DEVICE MARKET BY SPINAL CORD STIMULATORS 2019-2027 ($ MILLION)
FIGURE 4 EUROPE NEUROSTIMULATION DEVICE MARKET BY DEEP BRAIN STIMULATORS 2019-2027 ($ MILLION)
FIGURE 5 EUROPE NEUROSTIMULATION DEVICE MARKET BY SACRAL NERVE STIMULATORS 2019-2027 ($ MILLION)
FIGURE 6 EUROPE NEUROSTIMULATION DEVICE MARKET BY VAGUS NERVE STIMULATORS 2019-2027 ($ MILLION)
FIGURE 7 EUROPE NEUROSTIMULATION DEVICE MARKET BY GASTRIC ELECTRIC STIMULATOR 2019-2027 ($ MILLION)
FIGURE 8 EUROPE NEUROSTIMULATION DEVICE MARKET BY OTHER SYSTEM 2019-2027 ($ MILLION)
FIGURE 9 EUROPE NEUROSTIMULATION DEVICE MARKET SHARE BY APPLICATIONS 2018 & 2027 (%)
FIGURE 10 EUROPE NEUROSTIMULATION DEVICE MARKET BY PAIN MANAGEMENT 2019-2027 ($ MILLION)
FIGURE 11 EUROPE NEUROSTIMULATION DEVICE MARKET BY EPILEPSY 2019-2027 ($ MILLION)
FIGURE 12 EUROPE NEUROSTIMULATION DEVICE MARKET BY ESSENTIAL TREMOR 2019-2027 ($ MILLION)
FIGURE 13 EUROPE NEUROSTIMULATION DEVICE MARKET BY URINARY AND FECAL INCONTINENCE 2019-2027 ($ MILLION)
FIGURE 14 EUROPE NEUROSTIMULATION DEVICE MARKET BY DEPRESSION 2019-2027 ($ MILLION)
FIGURE 15 EUROPE NEUROSTIMULATION DEVICE MARKET BY DYSTONIA 2019-2027 ($ MILLION)
FIGURE 16 EUROPE NEUROSTIMULATION DEVICE MARKET BY GASTROPARESIS 2019-2027 ($ MILLION)
FIGURE 17 EUROPE NEUROSTIMULATION DEVICE MARKET BY PARKINSON’S DISEASE 2019-2027 ($ MILLION)
FIGURE 18 EUROPE NEUROSTIMULATION DEVICE MARKET BY OTHER APPLICATIONS 2019-2027 ($ MILLION)
FIGURE 19 PORTER’S FIVE FORCE MODEL
FIGURE 20 PREVALENCE OF MENTAL HEALTH DISORDERS ACROSS THE GLOBE BETWEEN PERIOD 2012 AND 2020 (MILLION)
FIGURE 21 RISING GERIATRIC POPULATION ACROSS THE GLOBE FOR PERIOD 2014-2020 (MILLION)
FIGURE 22 VALUE CHAIN OF NEUROSTIMULATION DRUGS
FIGURE 23 THE UNITED KINGDOM NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 24 FRANCE NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 25 GERMANY NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 26 SPAIN NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 27 ITALY NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 28 REST OF EUROPE NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
FIGURE 29 NEUROSTIMULATION DEVICE COMPANY MARKET SHARE 2018 (%)

 

List of Tables


TABLE LIST
TABLE 1 EUROPE NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
TABLE 2 EUROPE NEUROSTIMULATION DEVICE MARKET BY SYSTEM 2019-2027 ($ MILLION)
TABLE 3 EUROPE SPINAL CORD STIMULATORS MARKET 2019-2027 ($ MILLION)
TABLE 4 EUROPE DEEP BRAIN STIMULATORS MARKET 2019-2027 ($ MILLION)
TABLE 5 EUROPE SACRAL NERVE STIMULATORS MARKET 2019-2027 ($ MILLION)
TABLE 6 EUROPE VAGUS NERVE STIMULATORS MARKET 2019-2027 ($ MILLION)
TABLE 7 EUROPE GASTRIC ELECTRIC STIMULATOR MARKET 2019-2027 ($ MILLION)
TABLE 8 EUROPE OTHER SYSTEM MARKET 2019-2027 ($ MILLION)
TABLE 9 EUROPE NEUROSTIMULATION DEVICE MARKET BY APPLICATIONS 2019-2027 ($ MILLION)
TABLE 10 EUROPE PAIN MANAGEMENT MARKET 2019-2027 ($ MILLION)
TABLE 11 EUROPE EPILEPSY MARKET 2019-2027 ($ MILLION)
TABLE 12 EUROPE ESSENTIAL TREMOR MARKET 2019-2027 ($ MILLION)
TABLE 13 EUROPE URINARY AND FECAL INCONTINENCE MARKET 2019-2027 ($ MILLION)
TABLE 14 EUROPE DEPRESSION MARKET 2019-2027 ($ MILLION)
TABLE 15 EUROPE DYSTONIA MARKET 2019-2027 ($ MILLION)
TABLE 16 EUROPE GASTROPARESIS MARKET 2019-2027 ($ MILLION)
TABLE 17 EUROPE PARKINSON’S DISEASE MARKET 2019-2027 ($ MILLION)
TABLE 18 EUROPE OTHER APPLICATIONS MARKET 2019-2027 ($ MILLION)
TABLE 19 EUROPE NEUROSTIMULATION DEVICE MARKET BY GEOGRAPHY 2019-2027, (IN $ BILLION)
TABLE 20 EUROPE NEUROSTIMULATION DEVICE MARKET BY COUNTRY 2019-2027 ($ MILLION)